Protagenic Therapeutics, Inc. (PTIX)
0.7199
-0.02
(-2.05%)
USD |
OTCM |
Oct 23, 16:00
Protagenic Therapeutics Enterprise Value : 0.7372M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 0.7372M |
| October 22, 2026 | 0.7645M |
| October 21, 2026 | 0.7373M |
| October 20, 2026 | 0.7917M |
| October 19, 2026 | 0.7917M |
| October 16, 2026 | 0.7917M |
| October 15, 2026 | 0.7917M |
| October 14, 2026 | 0.8822M |
| October 13, 2026 | 0.893M |
| October 12, 2026 | 0.893M |
| October 09, 2026 | 0.8279M |
| October 08, 2026 | 0.8279M |
| October 07, 2026 | 0.8279M |
| October 06, 2026 | 0.8279M |
| October 05, 2026 | 0.8349M |
| October 02, 2026 | 0.8349M |
| October 01, 2026 | 0.846M |
| September 30, 2026 | 0.9003M |
| September 29, 2026 | 0.8962M |
| September 28, 2026 | 0.846M |
| September 25, 2026 | 0.8349M |
| September 24, 2026 | 0.9118M |
| September 23, 2026 | 0.9908M |
| September 22, 2026 | 0.9908M |
| September 21, 2026 | 1.074M |
| Date | Value |
|---|---|
| September 18, 2026 | 1.089M |
| September 17, 2026 | 0.7533M |
| September 16, 2026 | 0.9546M |
| September 15, 2026 | 0.8641M |
| September 14, 2026 | 0.9365M |
| September 11, 2026 | 1.011M |
| September 10, 2026 | 1.011M |
| September 09, 2026 | 1.099M |
| September 08, 2026 | 1.291M |
| September 04, 2026 | 1.353M |
| September 03, 2026 | 1.244M |
| September 02, 2026 | 1.335M |
| September 01, 2026 | 1.588M |
| August 31, 2026 | 1.606M |
| August 28, 2026 | 1.208M |
| August 27, 2026 | 1.127M |
| August 26, 2026 | 1.045M |
| August 25, 2026 | 1.154M |
| August 24, 2026 | 1.407M |
| August 21, 2026 | 0.8842M |
| August 20, 2026 | 0.5201M |
| August 19, 2026 | 0.0676M |
| August 18, 2026 | 0.0857M |
| August 17, 2026 | 0.0857M |
| August 14, 2026 | 0.0857M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9636M |
| Total Expenses (Quarterly) | 0.9636M |
| EPS Diluted (Quarterly) | -0.5323 |
| Earnings Yield | 409.6% |
| Normalized Earnings Yield | 285.76 |